Research programme: anti-interleukin-6 antibody - EUSA/Vaccinex

Drug Profile

Research programme: anti-interleukin-6 antibody - EUSA/Vaccinex

Latest Information Update: 14 Jun 2012

Price : $50

At a glance

  • Originator Vaccinex
  • Developer EUSA Pharma; Vaccinex
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Haematological malignancies; Rheumatoid arthritis

Most Recent Events

  • 12 Jun 2012 EUSA Pharma has been acquired by Jazz Pharmaceuticals plc
  • 04 Oct 2007 Preclinical trials in Rheumatoid arthritis in United Kingdom (Parenteral)
  • 04 Oct 2007 Preclinical trials in Rheumatoid arthritis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top